ascrinvacumab + erfonrilimab

**ascrinvacumab (GT90001)** is a fully humanized IgG2 monoclonal antibody targeting activin receptor-like kinase 1 (ALK-1). It acts as an antagonist of the TGF-beta/ALK-5 signaling pathway by binding to ALK-1 and its ligands BMP9 and BMP10. This inhibits tumor angiogenesis by blocking vascular maturation signals, reducing blood flow and vascularization in tumors. Developed as a first-in-class agent for solid tumors, it is licensed globally to Kintor Pharmaceutical from Pfizer[2]. **erfonrilimab (KN046)** is a recombinant humanized bispecific antibody that targets both programmed death ligand 1 (PD-L1) and cytotoxic T lymphocyte-associated protein 4 (CTLA-4). It consists of single-domain antibodies against PD-L1 and CTLA-4 fused with an IgG1 Fc domain. By simultaneously blocking PD-L1/PD-1 and CTLA-4/CD80-CD86 interactions, it enhances antitumor immune responses while depleting regulatory T cells in the tumor microenvironment. KN046 was invented by Alphamab Oncology[2][5][8]. The combination of GT90001 plus KN046 is being investigated for advanced or refractory solid tumors including hepatocellular carcinoma, gastric carcinoma/gastroesophageal junction adenocarcinoma, urothelial carcinoma, esophageal squamous cell carcinoma, neuroblastoma, and other neoplasms in Phase Ib/II clinical trials[6][1]. The combination aims to synergistically inhibit tumor angiogenesis while enhancing immune-mediated antitumor activity.

Other names

ascrinvacumaberfonrilimab